7 February 2022 - Advice on six new medicines for use in conditions including a rare lung cancer caused by occupational exposure to asbestos and also for a severely disabling muscle wasting disease has today been published by the Scottish Medicines Consortium.

Nivolumab (Opdivo) was accepted for the treatment of advanced malignant pleural mesothelioma, a type of lung cancer caused by exposure to asbestos that affects the thin membrane that lines the lungs.

Read SMC press release